SARS in 2012, MERS in 2012) mutated at a similar rate. Although this rate is not half as slow as the mutation rate of the influenza virus, influenza is already a virus that we can produce a vaccine against every year. Therefore, "vaccine development" is more critical than drugs. According to the latest information (normal update) released by the World Health Organization (WHO) on June 2, 10 candidate vaccines have entered the clinical trial stage, and 123 candidate vaccines are in the pre-clinical trial stage.
Judging from whatsapp database these 10 recent trials that are most likely to successfully develop a vaccine, there are few vaccine industry leaders (such as Pfizer Pfizer, MSD MSD, GlaxoSmithKline GSK, Sanofi and Johnson & Johnson), these large The company has not been as aggressively developing a vaccine as had hoped. Brad Loncar, biotech investor and CEO of Loncar Investments in the United States, pointed out: "It is very difficult to successfully develop a preventive vaccine or treatment to solve a public health crisis, especially with a lot of time and money costs." It can be seen that vaccine development is easier said than done, amazing R&D costs, risks and uncertainties make the leaders dare not bear it, so there is a lack of interest .
However, despite the high threshold of vaccine research and development, there are still countries and companies willing to invest. They are just interested in its publicity, the effectiveness of building international reputation, the opportunity to raise more investment funds, and the potential to increase economic decline. . In the global epidemic situation, most countries adopted the strategy of closing cities to delay the epidemic, which resulted in economic shutdown; the related economic losses were even greater than the financial turmoil in 2008, and this wave of economic recession may last until 2021 or even longer. Therefore, in addition to the public health level of epidemic control this time, how to reopen the society and revive the economy is more important to all countries.